michigan semaglutide constipation lawsuit glp-1 gastric intestinal obstruction attorney in kentucky law office bowel west virginia firm kentucky semaglutide gastrointestinal obstruction law firm GLP-1 medications are the hottest – michigan semaglutide bowel obstruction legal

Endocrinology 158 (6), 17011714

Regardless, constipation can contribute to UTIs, and it is well known that both GLP-1 and GLP-1/GIPs, such as tirzepatide, cause decreased GI motility as one of the ways they assist in weight reduction

M.RomanelliM.MargolisD.KappS.et al (2022)

Clinical trials vs real-world results What the clinical trials show The landmark SURMOUNT-5 trial published in 2025 compared these medications directly at standard maximum doses: 1 Mounjaro (tirzepatide 15 mg) produced 20.2% average weight loss Wegovy (semaglutide 2.4 mg) produced 13.7% average weight loss The 6.5 percentage point difference was statistically significant This trial used the maximum approved doses at the time (Mounjaro 15 mg, Wegovy 2.4 mg) and lasted 72 weeks